Pro-Pharmaceuticals, Inc. (PRWP.OB) Ships First Order of Revolutionary Cancer Therapeutic DAVANT® to South American Distributor PROCAPS S.A.
Pro-Pharmaceuticals, www.pro-pharmaceuticals.com – the tip of the spear in the fight against cancer and fibrosis via revolutionary therapeutics based on Galectin receptors, reported that the Company’s leading candidate DAVANAT® shipped its first commercial order ($200k value) to Colombia-based pharmaceutical giant PROCAPS S.A. today. CEO of PRWP, Theodore D. Zucconi, Ph.D., hailed the shipment as a “milestone” for the Company and stressed the efforts taken by PRWP to ensure that external variables related to such “first-time, international shipments of pharmaceutical products” were solidified. PROCAPS received exclusive rights earlier this year to market/sell DAVANAT in Columbia and Latin America, accepting responsibility for…